Codexis (CDXS) Non-Current Assets (2010 - 2026)
Codexis' (CDXS) quarterly Non-Current Assets came in at $49.7 million in Q1 2026, down 2.66% year-on-year from $51.1 million in Q1 2025, and down 2.47% quarter-over-quarter from $51.0 million in Q4 2025.
Codexis (CDXS) Non-Current Assets (2010 - 2026) Analysis & Trends
Codexis' Non-Current Assets history runs 17 years deep, the most recent figure standing at $49.7 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 2.66% year-over-year to $49.7 million in Q1 2026; TTM through Mar 2026 was $198.0 million, a 11.73% increase from a year earlier, with the FY2025 full-year figure at $51.0 million, up 1.48% from the prior year.
- Non-Current Assets fell to $49.7 million in Q1 2026 per CDXS's latest filing, from $51.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $90.4 million in Q1 2022 and bottomed at $35.3 million in Q3 2024.
- The 5-year median for Non-Current Assets is $51.0 million (2025), against an average of $61.4 million.
- Across the five-year window, Non-Current Assets surged 134.17% in 2022 and sank 53.17% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $87.5 million in 2022, then sank by 50.75% to $43.1 million in 2023, then grew by 16.58% to $50.2 million in 2024, then climbed by 1.48% to $51.0 million in 2025, then declined by 2.47% to $49.7 million in 2026.
- Per Business Quant, the three latest CDXS Non-Current Assets figures stand at $49.7 million (Q1 2026), $51.0 million (Q4 2025), and $47.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Codexis | 180.63 Mn | 115.49 Mn | 13.18 Mn | 49.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.72 Mn |
| Dec 31, 2025 | 50.98 Mn |
| Sep 30, 2025 | 47.77 Mn |
| Jun 30, 2025 | 49.52 Mn |
| Mar 31, 2025 | 51.08 Mn |
| Dec 31, 2024 | 50.24 Mn |
| Sep 30, 2024 | 35.28 Mn |
| Jun 30, 2024 | 40.61 Mn |
| Mar 31, 2024 | 41.61 Mn |
| Dec 31, 2023 | 43.10 Mn |
| Sep 30, 2023 | 51.44 Mn |
| Jun 30, 2023 | 86.72 Mn |
| Mar 31, 2023 | 88.11 Mn |
| Dec 31, 2022 | 87.50 Mn |
| Sep 30, 2022 | 89.29 Mn |
| Jun 30, 2022 | 89.69 Mn |
| Mar 31, 2022 | 90.41 Mn |
| Dec 31, 2021 | 84.50 Mn |
| Sep 30, 2021 | 53.44 Mn |
| Jun 30, 2021 | 39.92 Mn |